Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion
Condition(s) studied
Investigational drug(s) / intervention(s)
Routine endoscopy with artificial intelligence-assisted interpretation: (1) Improved detection of H. pylori infection, leading to timely eradication therapy. (2) Earlier identification of premalignant gastric conditions, facilitating appropriate surveillance endoscopy.
Study summary
The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.
Eligibility
Primary outcome measure(s)
- Gastric cancer-specific mortality — Up to 5 years
The primary endpoint is gastric cancer-specific mortality.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Yi-Chia Lee | Taipei | Taiwan | Recruiting |
More National Taiwan University Hospital trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05762991 on ClinicalTrials.gov ↗ ← All trials in Taiwan